Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inosine in Multiple Sclerosis
NCT00067327Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2002
- Countries
- 1
- Sponsor
- National Center for Complementary and Integrative Health
- Modality
- Small Molecules
- Drugs
- inosine
- Conditions
- multiple sclerosis (MS)
01
Overview
Phase 2, randomised trial of inosine in multiple sclerosis (MS), sponsored by National Center for Complementary and Integrative Health. Primary endpoints: Cumulative number of newly active lesions on MRI and Safety and tolerability of inosine. Started Feb 2002; status: completed.
02
Design
1 arm- Study design
- Randomized
Inosine
Patients receiving daily oral administration of inosine to raise serum uric acid levels.
03
Who it enrols
Patients with clinically definite RRMS or probable MS with recent relapse and MRI lesions, EDSS <= 5.0, and low serum uric acid (< 5 mg/dl), excluding those on recent immune-modifying treatments or corticosteroids.
04
Endpoints
Primary
Cumulative number of newly active lesions on MRI
Safety and tolerability of inosine
Beyond the preview
Go deeper on NCT00067327.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00067327.